The Bioscience Association of Maine strongly opposes LD 1422, “An Act To Allow Maine Residents To Personally Import Medications as Permitted under the Federal Food, Drug, and Cosmetic Act”. This legislation, if passed, will present a great risk to the public health of Maine residents and will also open the State of Maine to additional costly and unnecessary litigation. BAM is of the opinion that the legislation outlined in LD 1422 is misguided and we feel inappropriately addresses the issue it purportedly seeks to remedy. Read full statement here
Bioscience Association of Maine Strongly Opposes LD 1422
Related Posts
On the Record: Startup aims to turn scientific researchers into ‘deep-tech’ entrepreneurs
Justin Hafner, founder and former CEO of digital health startup Kinotek, aims to make an even bigger splash in the startup world...
Skincare startup funds UMaine scholarship to spark innovation
Marin Skincare, known for its Lobster Lotion product, partnered with the University of Maine to create a scholarship to spur innovation and...
Bigelow Lab looks to create ‘blue’ biotechnology businesses and jobs
Bigelow Laboratory for Ocean Sciences, an East Boothbay nonprofit research institute focused on global ocean health, last week launched a program...